Mountain Group Capital

Mountain Group News

Latest News

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

RESEARCH TRIANGLE PARK, N.C., April 16, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with Tagrisso® (osimertinib) in people with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC). AstraZeneca (LON: AZN) is providing Tagrisso for this trial under a non-exclusive clinical trial collaboration agreement. “G1T38 inhibits tumor cell…

Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

New consensus recommendations include test class result to guide risk-appropriate surveillance plans

Friendswood, Texas – March 26 – Castle Biosciences, Inc., today announced that the National Comprehensive Cancer Network (NCCN) has included the DecisionDx®-UM gene expression profile (GEP) test class results in their new clinical practice guidelines for uveal melanoma. These recommendations, released on March 15, 2018, are the first-ever NCCN guidelines for uveal melanoma, and their publication is an important milestone in the care of patients with this rare eye cancer….

G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Bene ts in Patients with Small Cell Lung Cancer

Statistically signi cant results highlight bene t of trilaciclib in several prospectively-de ned parameters, including: Grade 4 neutropenia, G-CSF usage, and chemotherapy dose reductions and delays Clinically meaningful data favoring trilaciclib versus placebo, including: febrile neutropenia, Grade 3/4 anemia, and red blood cell transfusions Management to host webcast and conference call today at 8 a.m. EST RESEARCH TRIANGLE PARK, N.C., March 05, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX),…

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

Primary Endpoint Achieved – Statistically Significant Improvement in Proportion of Patients Gaining 15 or More Letters in Visual Acuity All Key Secondary Endpoints Achieved

ALPHARETTA, Ga., March 05, 2018 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS- TA in patients with macular edema associated with non-infectious uveitis. Suprachoroidal CLS-TA is Clearside’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via…

Shell Takes a Major Stake in US Solar Developer Silicon Ranch

Shell seeks to expand its global New Energies footprint by acquiring a 44 percent interest in the Nashville-based solar company.

International energy giant Shell has signed a deal to become the largest shareholder of U.S. solar project developer, owner and operator Silicon Ranch Corporation. Under the agreement announced today, Shell will acquire a 43.83 percent interest in Nashville-based Silicon Ranch from Partners Group, a global private markets investment manager. The deal is valued at up to $217 million in cash, based on Silicon Ranch’s performance. Shell has the ability to…

Shell Acquires Interest in Silicon Ranch Corporation

Platform investment aligns Shell with best-in-class U.S. developer, owner, and operator of solar facilities

NASHVILLE, Tenn., Jan. 15, 2018 /PRNewswire/ — Silicon Ranch Corporation, a leading U.S. developer, owner, and operator of solar energy plants, announced today that it has signed an agreement to make Shell its largest shareholder. As part of the agreement, Shell will acquire a 43.83% interest in Silicon Ranch from Partners Group, the global private markets investment manager, for up to $217 million in cash based on Silicon Ranch performance, with the possibility to increase…

AgTech Accelerator Launches First Investment in Novel Fungicide Company, Boragen Inc., with $10 Million Series A Financing

RESEARCH TRIANGLE PARK, N.C. – March 2, 2017 – AgTech AcceleratorTM, the unique startup accelerator vehicle dedicated to emerging agricultural technologies, today announced the launch of its first AgTech startup, Boragen Inc., with a $10 million Series A financing round. Boragen is developing a novel synthetic chemistry platform, initially focusing on next-generation fungicides aimed to mitigate pest resistance and allow for more sustainable farming methods. Boragen’s versatile approach also has…

AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing

AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing AgTech Accelerator Invests in Second Emerging Company RESEARCH TRIANGLE PARK, N.C. – April 13, 2017 – AgTech AcceleratorTM, the RTP- based venture development organization focused on emerging agricultural technology and animal health companies, today announced a $5 million Series A investment into Skyline Vet Pharma, Inc. The investors participating in Skyline’s financing…

G1 Therapeutics Added to Nasdaq Biotechnology Index

RESEARCH TRIANGLE PARK, N.C., Dec. 18, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective prior to market open on Monday, December 18, 2017. The Nasdaq Biotechnology Index (NBI) contains securities of Nasdaq-listed companies classified as either biotechnology or pharmaceutical, according to the Industry Classification Benchmark. Companies in the NBI must…

G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after market close on September 15, 2017, as part of Russell’s quarterly addition of companies with recent initial public offerings. The Russell 2000 Index measures the performance of the small-cap segment of the U.S….

Next Page →